Ubs Asset Management Americas Inc Ironwood Pharmaceuticals Inc Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 269,725 shares of IRWD stock, worth $1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

269,725

Previous 308,690 12.62%

Holding current value

$1 Million

Previous $2.01 Million 44.93%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.93 - $7.04 $153,132 - $274,313	-38,965 Reduced 12.62%	269,725 $1.11 Million
Q2 2024 Aug 13, 2024	BUY	$5.58 - $8.61 $882,616 - $1.36 Million	158,175 Added 105.09%	308,690 $2.01 Million
Q1 2024 May 15, 2024	SELL	$8.32 - $15.45 $53,971 - $100,224	-6,487 Reduced 4.13%	150,515 $1.31 Million
Q4 2023 Feb 14, 2024	BUY	$8.79 - $11.51 $202,925 - $265,719	23,086 Added 17.24%	157,002 $1.8 Million
Q3 2023 Nov 13, 2023	SELL	$8.25 - $11.35 $185,253 - $254,864	-22,455 Reduced 14.36%	133,916 $1.29 Million
Q1 2023 May 15, 2023	SELL	$10.37 - $12.56 $93,153 - $112,826	-8,983 Reduced 5.43%	156,371 $1.65 Million
Q4 2022 Feb 14, 2023	BUY	$9.9 - $12.43 $368,329 - $462,458	37,205 Added 29.03%	165,354 $2.05 Million
Q3 2022 Nov 14, 2022	BUY	$10.14 - $12.38 $115,210 - $140,661	11,362 Added 9.73%	128,149 $1.33 Million
Q2 2022 Aug 12, 2022	SELL	$11.05 - $12.72 $1.36 Million - $1.57 Million	-123,285 Reduced 51.35%	116,787 $1.35 Million
Q4 2021 Feb 14, 2022	SELL	$10.86 - $13.95 $10.7 Million - $13.8 Million	-989,038 Reduced 80.47%	240,072 $2.8 Million
Q3 2021 Nov 15, 2021	SELL	$11.92 - $13.92 $8.06 Million - $9.41 Million	-676,165 Reduced 35.49%	1,229,110 $16.1 Million
Q2 2021 Aug 16, 2021	BUY	$10.16 - $13.11 $499,760 - $644,867	49,189 Added 2.65%	1,905,275 $24.5 Million
Q1 2021 May 14, 2021	SELL	$9.04 - $11.86 $5.32 Million - $6.98 Million	-588,177 Reduced 24.06%	1,856,086 $20.8 Million
Q4 2020 Mar 01, 2021	SELL	$9.05 - $12.2 $9.14 Million - $12.3 Million	-1,009,979 Reduced 29.24%	2,444,263 $27.8 Million
Q3 2020 Nov 13, 2020	SELL	$8.99 - $10.74 $26.8 Million - $32.1 Million	-2,986,625 Reduced 46.37%	3,454,242 $31.1 Million
Q2 2020 Aug 14, 2020	SELL	$9.14 - $11.97 $12.9 Million - $16.9 Million	-1,415,024 Reduced 18.01%	6,440,867 $66.5 Million
Q1 2020 May 15, 2020	SELL	$8.58 - $14.01 $7.62 Million - $12.4 Million	-888,342 Reduced 10.16%	7,855,891 $79.3 Million
Q4 2019 Feb 14, 2020	SELL	$8.22 - $14.0 $15.7 Million - $26.8 Million	-1,913,331 Reduced 17.95%	8,744,233 $116 Million
Q3 2019 Nov 14, 2019	BUY	$8.59 - $10.96 $3.94 Million - $5.03 Million	458,799 Added 4.5%	10,657,564 $91.5 Million
Q2 2019 Aug 15, 2019	BUY	$9.8 - $12.89 $30.1 Million - $39.6 Million	3,074,732 Added 43.16%	10,198,765 $0
Q1 2019 May 14, 2019	SELL	$8.27 - $12.73 $2.06 Million - $3.17 Million	-248,626 Reduced 3.37%	7,124,033 $0
Q4 2018 Feb 13, 2019	BUY	$7.8 - $16.13 $9.24 Million - $19.1 Million	1,184,060 Added 19.13%	7,372,659 $64 Million
Q3 2018 Nov 14, 2018	SELL	$14.31 - $17.65 $3.9 Million - $4.81 Million	-272,531 Reduced 4.22%	6,188,599 $0
Q2 2018 Aug 14, 2018	BUY	$11.83 - $16.2 $8.1 Million - $11.1 Million	684,368 Added 11.85%	6,461,130 $0
Q1 2018 May 14, 2018	SELL	$11.13 - $13.63 $6.47 Million - $7.93 Million	-581,592 Reduced 9.15%	5,776,762 $0
Q4 2017 Feb 09, 2018	SELL	$12.16 - $14.58 $594,076 - $712,305	-48,855 Reduced 0.76%	6,358,354 $0
Q3 2017 Nov 13, 2017	BUY	$12.07 - $14.87 $77.3 Million - $95.3 Million	6,407,209	6,407,209 $0

Others Institutions Holding IRWD

# of Institutions

231

Shares Held

162M

Call Options Held

11.2M

Put Options Held

9.1K

View Full List

About IRONWOOD PHARMACEUTICALS INC

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $570M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

More about IRWD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Ironwood Pharmaceuticals Inc Transaction History